Ironwood Pharmaceuticals (IRWD, Financial) experienced a significant stock decline of 5.12%, with its shares trading at $3.62. The trading volume reached 487,268 shares, reflecting a turnover rate of 0.30% and a price fluctuation amplitude of 4.20%.
Financially, Ironwood reported a revenue of $91.59 million, a net profit of $3.65 million, and earnings per share of $0.02. The company's gross profit stood at $91.09 million, with a price-to-earnings ratio of -363.00. Among the seven institutions that rated the stock, 86% recommended buying, while 14% suggested holding, with no sell recommendations.
In the pharmaceutical industry, where Ironwood operates, the sector saw an overall increase of 1.46%. Notable performers in the sector included Procaps Group S.A., Alpha Teknova, Inc., and Mira Pharmaceuticals, Inc., with significant price movements and trading activities. Specifically, Procaps Group S.A. had a remarkable fluctuation of 133.93%, while Alpha Teknova, Inc. and Mira Pharmaceuticals, Inc. saw fluctuations of 29.95% and 19.64%, respectively.
Ironwood Pharmaceuticals focuses on developing specialty and generic drugs in areas with unmet needs, such as irritable bowel syndrome with constipation, chronic idiopathic constipation, uncontrolled gout-related hyperuricemia, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company aims to expand its research, manufacturing, and marketing capabilities through collaborative licensing, commercial agreements, and acquisitions.
